# Linagliptin Inpatient Trial

Study · id `cardio:ct-nct02004366` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02004366](<https://clinicaltrials.gov/study/NCT02004366>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02004366

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 295 participants.

## Technical summary

Registry record NCT02004366. Randomized; no masking; primary purpose treatment. Start 2014-01 (actual); primary completion 2017-02 (actual). Results posted on 2018-10-30.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 295 participants (enrolled count; ClinicalTrials.gov record NCT02004366, source copy `cardio:ctgov-nct02004366-2019-02-20`, retrieved 2026-10-26)
- Started: 2014-01 (actual) (ClinicalTrials.gov record NCT02004366, source copy `cardio:ctgov-nct02004366-2019-02-20`, retrieved 2026-10-26)
- Primary completion: 2017-02 (actual) (ClinicalTrials.gov record NCT02004366, source copy `cardio:ctgov-nct02004366-2019-02-20`, retrieved 2026-10-26)
- Completion: 2017-03 (actual) (ClinicalTrials.gov record NCT02004366, source copy `cardio:ctgov-nct02004366-2019-02-20`, retrieved 2026-10-26)
- Results first posted: 2018-10-30 (ClinicalTrials.gov record NCT02004366, source copy `cardio:ctgov-nct02004366-2019-02-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02004366, source copy `cardio:ctgov-nct02004366-2019-02-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02004366-2019-02-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Linagliptin Inpatient Trial
- Condition: Type 2 Diabetes
- Intervention (Drug): Linagliptin
- Intervention (Drug): Basal Bolus
- Intervention (Drug): Linagliptin
- Intervention (Drug): Linagliptin + 50% Glargine dose on discharge
- Intervention (Drug): Linagliptin + 80% Glargine
- Lead sponsor: Emory University
- Lead sponsor class: OTHER
- Collaborator: Boston Medical Center
- Collaborator class: OTHER
- Collaborator: Rush University
- Collaborator class: OTHER
- Collaborator: University of Denver
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Emory University (`cardio:org-emory-university`)
- Registry lists this organization as a collaborator: Boston Medical Center (`cardio:org-boston-medical-center`)

## Provenance

Content hash: 7901df4e47b6e2e490e9f7358a5175f7ff3c82ee664c129a561d387aa64a2c4a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
